Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Affymetrix Gene Chip Users

Articles with lock require a subscription to GLG News | Request a free trial
July 11, 2008
How to identify individuals likely to benefit from the use of Statins.
Analysis of: 8-Year-Olds on Statins? A New Plan Quickly Bites Back | www.nytimes.com
Author: GLG Expert Contributor
Widespread use of statins is likely to reduce the incidence of heart attacks and strokes and reduce the process responsible: atherosclerosis. Statins are expensive and selection of individuals and children at high to moderate risk should go beyond risk stratification by standard means and...
January 25, 2008
1000 genomes - personalized medicine on sight
Analysis of: Detailed gene map 'within grasp' - 1000 human genomes to be mapped | news.bbc.co.uk
Author: GLG Expert Contributor
This is a major project that will change teh way we view genome analysis and personalized medicine. For the first time, we will have almost complete information on the DNA sequence of more than 1000 individuals. It will allow the development of methodologies to generate data and interpret genetic information. There...
February 21, 2007
generic biotech drugs
Analysis of: Bill Would Allow Copying of Biotech Drugs | www.nytimes.com
Author: GLG Expert Contributor
Long feared option for FDA. The argument that biologics are "so complicated" needs another look. May be after years of biologics we learned it is not that specific nor that complicated. This decision may affect the price of small molecules and biologics and seems a breakthrough in thinking. Generic...

Page : 11 to 3 of 3

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T17:45:17.637